Stent production should match that of past 3 months: NPPA

Regulator received 30 complaints of overcharging; probe in these cases underway

Meeting manufacturers to discuss the availability of stents in the market, the National Pharmaceutical Pricing Authority (NPPA) has asked them to ensure their production and distribution is on a par with their production in the three months before the price cap came into force. A manufacturer who attended the meeting told Business Standard the NPPA said the eight per cent margin was supposed to be for the manufacturer and distributor and not the hospital, unless it uses its registered pharmacy to source stents. 

Last week, the regulator had invited 16 firms, including Abbott Healthcare, Boston Scientific India and Sahajanand Medical Technologies,